Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: AUTL

Autolus Therapeutics plc

Healthcare | Biotechnology

No licensed closing price on file for AUTL. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.06

Autolus Therapeutics plc (NASDAQ: AUTL) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 11:09 UTC.

What Autolus Therapeutics plc does

This is an early-stage biopharmaceutical company that develops and manufactures T cell therapies for cancer and autoimmune diseases using proprietary programming technologies. The company's first approved product, AUCATZYL, treats relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and has been launched in the United States and United Kingdom. Beyond AUCATZYL, the company is advancing the same therapy candidate in additional oncology indications including pediatric leukemia and lymphoma, as well as in autoimmune conditions such as lupus and multiple sclerosis.

Summarized from Autolus Therapeutics plc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.06

Revenue, margins & earnings

FY2023: net loss $208M on revenue $2M$2MFY2023FY2024: net loss $221M on revenue $10M$10MFY2024FY2025: net loss $288M on revenue $75M$75MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-03
  • 2026-09-03U.S. CCO & Country Gen ManagerOption exercise20,000$47.0K
  • 2026-09-03U.S. CCO & Country Gen ManagerSale-6,713$15.7K
  • 2026-09-03U.S. CCO & Country Gen ManagerRestricted Share UnitsOption exercise-20,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Autolus Therapeutics plc do?

This is an early-stage biopharmaceutical company that develops and manufactures T cell therapies for cancer and autoimmune diseases using proprietary programming technologies.

When did AUTL last file with the SEC?

Autolus Therapeutics plc's most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 11:09 UTC. This page is also available as JSON at /api/data?ticker=AUTL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AUTL and 5,000+ tickers.

Create a free account — keep AUTL
For your agent
GET /api/data?ticker=AUTL

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt